3Shibuya M.Vascular Endothelial Growth Factor(VEGF) and Its Re- ceptor(VEGFR) Signaling in Angiogenesis: A Crucial Target for Anti and Pro-Angiogenic Therapies[J].Genes Cancer, 2011,2 (12):1097-1105.
4Meyer A, Uder M, Lang W, et al. Visceral artery aneurysms[J]. Zentralbl Chir, 2010,135(5):416-420.
5Patruno R, Arpaia N, Gadalet CD, et al.VEGF concentration from plasma activated platelets rich correlates with microvascular densi- ty and grading in canine mast cell tumour spontaneous model[J]. Cell Mol Med,2009,13(3):555-561.
6Pooh RT, Ng IO, Lau C, et al. Serum vascular endothelial growth factor predicts venous invasion in hepatocellular carcinoma:a pro- spective sudy[J]. Ann Surg,2001,233(2):227-235.
7Mukozu T, Nagai H, Matsui D, et al. Serum VEGF as a tumor marker in patients with HCV-related liver cirrhosis and hepatocel- lular carcinoma [J]. Anticancer Res,2013 ,33(3):1013-1021.
8Tseng PL,Tai MH, Huang CC,et al. Overexpression of VEGF is associated with positive p53 immunostaining in hepatocellular carcinoma(HCC) and adverse outcome of HCC patients[J]. J Surg Oncol,2008,98(5) 1349.
9Thomas MB,Morris JS,Chadha R,et al. Phase Ⅱ trial of the combination of bevacizumab and erlotinib in patients who have advanced hepatocellular carcinoma[J]. J Clin Oncol,2009,27 (6) :843.
10Tang ZY, Ye SL, Liu YK, et al. A decade's studies on metastasis ofhepatocellular carcinoma[J]. J Cancer Res Clin Oncol, 2004, 130(4):187-196.
